RETIFANLIMAB

UNII: 2Y3T5IF01Z
Preferred Substance Name: RETIFANLIMAB

2079108-44-2
AEX1188
AEX-1188
ANTI-PD-1 MONOCLONAL ANTIBODY MGA012
IMMUNOGLOBULIN G4, ANTI-(HUMAN PROGRAMMED CELL DEATH PROTEIN 1) (HUMANIZED MONOCLONAL MGA012 .GAMMA.4-CHAIN), DISULFIDE WITH HUMANIZED MONOCLONAL MGA012 .KAPPA.-CHAIN, DIMER
INCMGA00012
INCMGA-00012
MGA012
MGA-012
RETIFANLIMAB [INN]
RETIFANLIMAB [USAN]
RETIFANLIMAB [WHO-DD]
RETIFANLIMAB-DLWR
ZYNYZ

Note

UNIIs are generated based on scientific identity characteristics using ISO 11238 data elements. UNII availability does not imply any regulatory review or approval. Synonyms and mappings are based on the best public information available at the time of publication. Please report any problems/errors associated with this data to FDA-SRS@fda.hhs.gov.

About, Contact Us, Copyright, Privacy, Accessibility

U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MD 20993-0002

U.S. Food and Drug Administration, Health & Human Services

Freedom of Information Act

RETIFANLIMAB

Synonyms and Mappings

Resources

Note